Are the physicochemical properties of antibacterial compounds really different from other drugs?

BackgroundIt is now widely recognized that there is an urgent need for new antibacterial drugs, with novel mechanisms of action, to combat the rise of multi-drug resistant bacteria. However, few new compounds are reaching the market. Antibacterial drug discovery projects often succeed in identifying potent molecules in biochemical assays but have been beset by difficulties in obtaining antibacterial activity. A commonly held view, based on analysis of marketed antibacterial compounds, is that antibacterial drugs possess very different physicochemical properties to other drugs, and that this profile is required for antibacterial activity.ResultsWe have re-examined this issue by performing a cheminformatics analysis of the literature data available in the ChEMBL database. The physicochemical properties of compounds with a recorded activity in an antibacterial assay were calculated and compared to two other datasets extracted from ChEMBL, marketed antibacterials and drugs marketed for other therapeutic indications. The chemical class of the compounds and Gram-negative/Gram-positive profile were also investigated. This analysis shows that compounds with antibacterial activity have physicochemical property profiles very similar to other drug classes.ConclusionsThe observation that many current antibacterial drugs lie in regions of physicochemical property space far from conventional small molecule therapeutics is correct. However, the inference that a compound must lie in one of these “outlier” regions in order to possess antibacterial activity is not supported by our analysis.

[1]  Dean G. Brown,et al.  Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. , 2014, Journal of medicinal chemistry.

[2]  C. Limberakis,et al.  Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitors , 2014, The Journal of Antibiotics.

[3]  Lori B. Pfahler,et al.  Lead Discovery Using Stochastic Cluster Analysis (SCA): A New Method for Clustering Structurally Similar Compounds , 1998, J. Chem. Inf. Comput. Sci..

[4]  B. Wanner,et al.  Characterization of Peptide Chain Length and Constituency Requirements for YejABEF-Mediated Uptake of Microcin C Analogues , 2011, Journal of bacteriology.

[5]  R. Tommasi,et al.  Toward the rational design of carbapenem uptake in Pseudomonas aeruginosa. , 2015, Chemistry & biology.

[6]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[7]  H. Moser,et al.  Physicochemical properties of antibacterial compounds: implications for drug discovery. , 2008, Journal of medicinal chemistry.

[8]  J. Manchester,et al.  A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV. , 2015, ACS infectious diseases.

[9]  Tudor I. Oprea,et al.  Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? , 2008, J. Comput. Aided Mol. Des..

[10]  Derek S. Tan,et al.  General Platform for Systematic Quantitative Evaluation of Small-Molecule Permeability in Bacteria , 2014, ACS chemical biology.

[11]  John P. Overington,et al.  The relationship between target-class and the physicochemical properties of antibacterial drugs , 2015, Bioorganic & medicinal chemistry.

[12]  J. Rozenski,et al.  Base substituted 5'-O-(N-isoleucyl)sulfamoyl nucleoside analogues as potential antibacterial agents. , 2014, Bioorganic & medicinal chemistry.

[13]  Dean G. Brown,et al.  ESKAPEing the labyrinth of antibacterial discovery , 2015, Nature Reviews Drug Discovery.

[14]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[15]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.